Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01DA021776-01A1 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Drug Abuse (NIDA) | NIH |
Not provided
Not provided
Not provided
Not provided
This study will evaluate the efficacy of ondansetron compared with placebo in the treatment of cocaine dependence.
We propose to conduct a 9 week randomized, controlled clinical trial to evaluate the efficacy of ondansetron 4 mg twice daily compared with placebo (total N = 100/group × 2 groups = 200 individuals randomized, 400 total subjects will be consented), provided as an adjunct to manual-driven, structured CBT + BBCET in the treatment of cocaine dependence.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ondansetron | Experimental | Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy |
|
| Placebo | Placebo Comparator | Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Ondansetron | Drug | 4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Cocaine Use by Self-report | Participants were assessed up to three times weekly for up to 9 weeks to evaluate cocaine use by self-report | up to 9 weeks |
| Cocaine Use by Urine Benzoylecgonine | Urine samples were collected up to three times weekly for up to 9 weeks to test for the major cocaine metabolite benzoylecgonine | up to 9 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Please contact site for additional information
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Nassima Ait-Daoud Tiouririne, M.D. | University of Virginia | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Virginia Center for Addiction Research and Education | Charlottesville | Virginia | 22911 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 34600264 | Derived | Blevins D, Seneviratne C, Wang XQ, Johnson BA, Ait-Daoud N. A randomized, double-blind, placebo-controlled trial of ondansetron for the treatment of cocaine use disorder with post hoc pharmacogenetic analysis. Drug Alcohol Depend. 2021 Nov 1;228:109074. doi: 10.1016/j.drugalcdep.2021.109074. Epub 2021 Sep 24. |
| Label | URL |
|---|---|
| (UVA CARE Website) | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Ondansetron | Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy Ondansetron: 4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy |
| FG001 | Placebo | Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy Placebo: twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy |
| Title | Milestones | Reasons Not Completed | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Ondansetron | Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy Ondansetron: 4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy |
| BG001 | Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Cocaine Use by Self-report | Participants were assessed up to three times weekly for up to 9 weeks to evaluate cocaine use by self-report | All participants who completed at least one randomly allocated treatment visit were included in the intent-to-treat population. | Posted | Mean | Standard Deviation | Percent of cocaine-free (abstinent)days | up to 9 weeks |
|
up to 9 weeks
Not provided
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Ondansetron | Ondansetron + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy Ondansetron: 4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hospitalization for gallstone | Hepatobiliary disorders | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Abdominal Pain | Gastrointestinal disorders | Systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Nassima Ait-Daoud Tiouririne, M.D. | University of Virginia | (434)243-0570 | nat7b@virginia.edu |
Not provided
| ID | Term |
|---|---|
| D019970 | Cocaine-Related Disorders |
| ID | Term |
|---|---|
| D019966 | Substance-Related Disorders |
| D064419 | Chemically-Induced Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
| ID | Term |
|---|---|
| D017294 | Ondansetron |
| D000073893 | Sugars |
| ID | Term |
|---|---|
| D007093 | Imidazoles |
| D001393 | Azoles |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D006571 | Heterocyclic Compounds |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Drug | twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy |
|
|
| University of Virginia Center for Addiction Research and Education |
| Richmond |
| Virginia |
| 23294 |
| United States |
Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
Placebo: twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
| BG002 | Total | Total of all reporting groups |
| Participants |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Number | participants |
|
|
|
|
| Primary | Cocaine Use by Urine Benzoylecgonine | Urine samples were collected up to three times weekly for up to 9 weeks to test for the major cocaine metabolite benzoylecgonine | All participants who completed at least one randomly allocated treatment visit were included in the intent-to-treat population. | Posted | Mean | Standard Deviation | Percent of cocaine-free urines | up to 9 weeks |
|
|
|
|
| 0 |
| 53 |
| 1 |
| 53 |
| 44 |
| 53 |
| EG001 | Placebo | Placebo + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy Placebo: twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy | 0 | 55 | 1 | 55 | 47 | 55 |
| Hospialization for stab wound to chest | Surgical and medical procedures | Systematic Assessment |
|
| Anxiety | Psychiatric disorders | Systematic Assessment |
|
| Appetite Increase | Gastrointestinal disorders | Systematic Assessment |
|
| Appetite Decrease | Gastrointestinal disorders | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | Systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | Systematic Assessment |
|
| Dizziness | Nervous system disorders | Systematic Assessment |
|
| Fatigue | Nervous system disorders | Systematic Assessment |
|
| Headache | Nervous system disorders | Systematic Assessment |
|
| Insomnia | Nervous system disorders | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | Systematic Assessment |
|
| Weight Decrease | Metabolism and nutrition disorders | Systematic Assessment |
|
| Weight Increase | Metabolism and nutrition disorders | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
| Paresthesia | Nervous system disorders | Systematic Assessment |
|
| Back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
|
| Depression | Psychiatric disorders | Systematic Assessment |
|
| Nausea | Gastrointestinal disorders | Systematic Assessment |
|
| Somnolence | Psychiatric disorders | Systematic Assessment |
|
Not provided
Not provided
| D002227 |
| Carbazoles |
| D007211 | Indoles |
| D006574 | Heterocyclic Compounds, 2-Ring |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D006575 | Heterocyclic Compounds, 3-Ring |
| D002241 | Carbohydrates |